Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
Jeffrey S. Weber, Sandra P. D’Angelo, David R. Minor et al. · The Lancet Oncology · 2015
Cited by 2,676 works. doi:10.1016/s1470-2045(15)70076-8
Authors
- Jeffrey S. Weber
- Sandra P. D’Angelo
- David R. Minor
- Frank Stephen Hodi
- Ralf Gutzmer
- Bart Neyns
- Christoph Höeller
- Nikhil I. Khushalani
- Wilson H. Miller
- Christopher D. Lao
- Gerald P. Linette
- Luc Thomas
- Paul C. Lorigan
- Kenneth F. Grossmann
- Jessica C. Hassel
- Michele Maio
- Mario Sznol
- Paolo A. Ascierto
- Peter Mohr
- Bartosz Chmielowski
References
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
- Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
- Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
- Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation
- Nivolumab in Previously Untreated Melanoma without BRAF Mutation
- Nivolumab plus Ipilimumab in Advanced Melanoma
- Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
- Development of Lupus-like Autoimmune Diseases by Disruption of the PD-1 Gene Encoding an ITIM Motif-Carrying Immunoreceptor